Hepatitis C patients wait for Maviret’s arrival.

Korean physicians and patients have expressed high expectations for AbbVie Korea’s Maviret (ingredient: glecaprevir/pibrentasvir), a chronic hepatitis C therapy that reduced the treatment time by one month, the company said.